Eterna Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
1.010
-0.060 (-5.62%)
Oct 11, 2024, 4:00 PM EDT - Market closed
Eterna Therapeutics Revenue
Eterna Therapeutics had revenue of $47.00K in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $162.00K. In the year 2023, Eterna Therapeutics had annual revenue of $68.00K.
Revenue (ttm)
$162.00K
Revenue Growth
n/a
P/S Ratio
33.74
Revenue / Employee
$20,250
Employees
8
Market Cap
5.46M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
IM Cannabis | 36.45M |
SunLink Health Systems | 32.44M |
Biomerica | 5.42M |
Vaccinex | 356.00K |
ABVC BioPharma | 136.40K |
Creative Medical Technology Holdings | 17.00K |
ERNA News
- 5 months ago - Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs - GlobeNewsWire
- 5 months ago - Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board - GlobeNewsWire
- 8 months ago - Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors - GlobeNewsWire
- 10 months ago - Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4) - GlobeNewsWire
- 10 months ago - Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer - GlobeNewsWire
- 10 months ago - Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing - GlobeNewsWire
- 1 year ago - Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors - GlobeNewsWire
- 1 year ago - Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics - GlobeNewsWire